New legislation in California would aim to curb opioid addiction; increasing number of generics are causing medicines to be more affordable; healthcarey company focused on serving low-income urban residents receives first round funding.
A California legislator has introduced new bills that hope to tackle opioid addiction by restricting access to the drugs. According to the Los Angeles Times, the 3 measures would build on the state database’s ability to track prescriptions and provide a clearer and more up-to-date picture of prescriptions. For instance, one of the measures would link the California database to other states in order to track doctor shopping across state lines.The availability of more generic alternatives and slowing price inflation are causing prescription medicines to become more affordable, according to CVS Health and Walgreens Boots Alliance. The companies said their pharmacy revenues are taking a hit from those changes, reported The Wall Street Journal. However, the companies both expect profits to increase since generics have a higher margin than brand-name drugs.A healthcare company focused on serving low-income urban residents has received $20.8 million in first-round funding from investors that include J Mario Molina, MD, and a new investment firm formed by Andy Slavitt, the former acting administrator for CMS under President Barack Obama. According to Reuters, Cityblock’s goal is trying to make it easier for low-income individuals in urban areas to get personalized care, such as preventive visits and accessing appropriate social services, in order to avoid unnecessary emergency department visits and prevent larger healthcare crises.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More